

West Virginia Medicaid Drug Utilization Review Board Minutes

May 23, 2018

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
Ernest Miller, DO
Kate Forman, PharmD
Myra Chiang, MD
John Vanin, MD
Scott Brown, RPh
C.K. Babcock, PharmD (via phone)
Michael Ballow, PharmD (via phone)
Christopher Booth, PharmD (via phone)

Members Absent:

K.C. Lovin, PA-C, Vice Chair
Michael Lonsinger, PharmD
John Guilfoose, MD

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, DUR Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Change Healthcare
Taylor DeRuiter, PharmD, Health Information Designs (HID)

I. INTRODUCTIONS

- A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:06 p.m. EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM February 28, 2018 DUR BOARD MEETING

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. OLD BUSINESS

- 1. None

IV. NEW BUSINESS

A. Speakers

- 1. Erin O'Rourke Sarepta Therapeutics Exondys 51

B. Updates from the April 25, 2018 Pharmacy & Therapeutics Committee Meeting

- 1. Dr. Labus and the Board reviewed the updates from the April 25, 2018 P&T meeting. No criteria changes were requested beyond those presented in section III-C of this document.

C. PDL Prior Authorization Criteria (Attachment A)

- 1. **Eucrisa** – A motion to approve the criteria as presented was made, seconded, and passed.
- 2. **Amitiza** – A motion to approve the criteria as presented was made, seconded, and passed.
- 3. **Linzess** – A motion to approve the criteria as presented was made, seconded, and passed.
- 4. **Sublocade** – A motion to approve the criteria as presented was made, seconded, and passed.
- 5. **Exondys 51** – A motion was made to amend the presented criteria to add a requirement that the following baseline lab information be provided with the request: blood urea nitrogen (BUN), creatinine clearance (CrCl), and liver function tests (LFTs). A motion to approve the amended criteria was made, seconded, and passed.
- 6. **Kalydeco** – A motion to approve the criteria as presented was made, seconded, and passed.
- 7. **Orkambi** – A motion to approve the criteria as presented was made, seconded, and passed.
- 8. **Symdeko** – A motion to approve the criteria as presented was made, seconded, and passed.

V. REPORTS

- A. **Molina Quarterly Report** – Eric Sears presented an overview of the Molina 2018 First Quarter Report (Attachment B). The presentation included a review of the DUR Quarterly Overall Summary Report.

- B. **Rational Drug Therapy Program** – Steve Small presented a review of the prior authorization program for the First Quarter 2018.

- C. **Health Information Designs** – Taylor DeRuiter presented an overview of the First Quarter 2018 retrospective drug utilization activity (Attachment C). The

presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, educational interventions completed, and evaluation of usefulness from the providers. Additionally, the Board requested utilization information be presented at the next Board meeting on the following topics: (a) concomitant utilization of sedative/hypnotics and other non-benzodiazepine medications commonly used for sedation; (b) concomitant utilization of a medication from two or more of the following drugs/drug classes: gabapentin, benzodiazepines, opiate analgesics, and gabapentin.

VI. OTHER BUSINESS – OPEN TO THE FLOOR

- A. None

VII. NEXT MEETING AND ADJOURNMENT

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:34 p.m. EDT.
- C. The next meeting will be Wednesday, September 26, 2018 from 4:00 p.m.–6:00 p.m. and located at WVDHHR.

Submitted by:

Taylor DeRuiter, PharmD, Health Information Designs